[1] Ascoli CA,Maul GG. Identification of a novel nuclear domain[J]. J Cell Biol, 1991,112(5):785-795.
[2] Andrade LE, Chan EK, Raska Ⅰ, et al. Human autoantibody to a novel protein of the nuclear coiled body: immunological characterization and cDNA cloning of p80coilin[J]. J Exp Med, 1991,173(6):1407-1419.
[3] Li C, Ao J, Fu J, et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1[J]. Oncogene, 2011,30(42):4350-4364.
[4] An J, Wang C, Deng Y, et al. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants[J]. Cell Rep, 2014,6(4):657-669.
[5] Zhang L, Peng S, Dai X, et al. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells[J]. Cancer Lett, 2017,390:11-20.
[6] Hu X, Yang Z, Zeng M, et al. Speckle-type POZ (pox virus and zinc finger protein) protein gene deletion in ovarian cancer: fluorescence in situ hybridization analysis of a tissue microarray[J]. Oncol Lett, 2016,12(1):658-662.
[7] Zeng C, Wang Y, Lu Q, et al. SPOP suppresses tumorigenesis by regulating Hedgehog/Gli2 signaling pathway in gastric cancer[J]. J Exp Clin Cancer Rese, 2014,33:75.
[8] Gao K, Jin X, Tang Y, et al. Tumor suppressor SPOP mediates the proteasomal degradation of progesterone receptors (PRs) in breast cancer cells[J]. Am J Cancer Res, 2015,5(10):3210-3220.
[9] El-Serag HB,Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis[J]. Gastroenterology, 2007,132(7):2557-2576.
[10] Lau WY,Lai EC. Hepatocellular carcinoma: current management and recent advances[J]. Hepatobiliary Pancreat Dis Int, 2008,7(3):237-257.
[11] Dahmani R, Just PA,Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2011,35(11):709-713.
[12] Komposch K,Sibilia M. EGFR signaling in liver diseases[J]. Int J Mol Sci, 2015,17(1):pii E30.
[13] Sia D, Alsinet C, Newell P, et al. VEGF signaling in cancer treatment[J]. Curr Pharm Des, 2014,20(17):2834-2842.
[14] Li G, Ci W, Karmakar S, et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer[J]. Cancer Cell, 2014,25(4):455-468.
[15] Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer[J]. Nat Genet, 2012,44(6):685-689. [16] Ding D, Song T, Jun W, et al. Decreased expression of the SPOP gene is associated with poor prognosis in glioma[J]. Int J Oncol, 2015,46(1):333-341.
[17] Luo J, Bao YC, Ji XX, et al. SPOP promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth[J]. Biochem Biophys Res Commun, 2017,483(2):880-884.
[18] Liu ChJ, Zhang XY, Shan ZhY, et al. Establishment of a tumor-bear mouse model carrying human HepG2 cells and exploration of immune tolerance[J]. Acta Anatomica Sinica, 2015, 46(4): 509-513. (in Chinese)
刘春佳, 张星宇, 单智焱, 等. 人肝癌HepG2细胞小鼠荷瘤模型的建立及免疫耐受的探讨[J]. 解剖学报, 2015,46(4):509-513. |